Detail akcie ADOCIA online

Business Summary: Adocia SA is a clinical-stage biotechnology company based in France. The Company specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Adocia SA revenues increased from EUR2.2M to EUR9.3M. Net loss decreased 56% to EUR9.3M. Revenues reflect Research and collaborative agreements increase from EUR313K to EUR9.3M. Lower net loss reflects France segment loss decrease of 48% to EUR7.4M. Basic Earnings per Share excluding Extraordinary Items increased from -EUR1.91 to -EUR0.63.